Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer.
